Biotech Values

[genisi]

Well, I think all those GPR119 receptor agonists have demonstrated meaningful results in preclinical models of diabetes (sustained glucose control in prediabetic ZDF rats and substantial body weight lowering in DIG rats), but some already disappointed with poor clinical efficacy. The only one with positive clinical data so far is PSN821. I couldn't find clinical data from MBX2982, but guess they weren't so shiny cause SNY abandoned ship after seeing phase IIa results. We'll have to wait and see if ARRY's candidate behaves itself with humans as it did with rats :)